Raloxifene
Evista. Second-generation SERM. Preferred over Tamoxifen for gynecomastia treatment and reversal due to stronger breast tissue selectivity.
Overview
Evista. Second-generation SERM. Preferred over Tamoxifen for gynecomastia treatment and reversal due to stronger breast tissue selectivity.
Blocks estrogen at breast tissue (more effective for existing gyno than Tamoxifen), weaker LH/FSH stimulation than Tamoxifen (less useful for PCT), beneficial for lipids, positive effect on bone density, does not raise SHBG as significantly as Tamoxifen
Compound Guide
Mechanism: Selective Estrogen Receptor Modulator. Acts as estrogen antagonist at breast tissue and bone, neutral/agonist at uterus (unlike Tamoxifen). Strongest SERM for breast tissue estrogen blockade.
Dosage:
- Gyno prevention (on cycle): 30mg/day
- Active gyno treatment / reversal: 60mg/day for 3-6 months
- Acute gyno flare: 60mg/day + Letrozole 2.5mg/day for 7-10 days, then Raloxifene 60mg/day alone
Administration:
- Oral tablet, once daily, with or without food
- Long treatment duration for gyno reversal — 3-6 months minimum
Key Notes:
- Gold standard for gyno reversal in bodybuilding — more tissue-selective than Tamoxifen
- Does NOT significantly stimulate LH/FSH — not useful as a primary PCT drug
- Can be run alongside Tamoxifen or Enclomiphene during PCT if gyno is a concern
- Studies show ~80% improvement in gynecomastia with 3-6 months of use at 60mg/day
- Beneficial for lipids — lowers LDL, raises HDL
- Well tolerated long-term — fewer side effects than Tamoxifen
- Monitor: lipids (generally improve), E2 (remains unchanged — Raloxifene blocks at the receptor, does not lower serum E2)
Usage History
Pairs With
How Raloxifene behaves when it is run alongside other compounds.
Commonly stacked with
Used to offset
Stacks the risk
Frequently Asked Questions
Quick Reference
Category
SERM
Half-Life
28 hours
Detection Time
N/A